PMID- 16331615
OWN - NLM
STAT- MEDLINE
DCOM- 20060428
LR  - 20201226
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 118
IP  - 9
DP  - 2006 May 1
TI  - Short-term dietary administration of celecoxib enhances the efficacy of tumor 
      lysate-pulsed dendritic cell vaccines in treating murine breast cancer.
PG  - 2220-31
AB  - Cyclooxygenase-2 (COX-2) is a rate-limiting enzyme in the synthesis of 
      prostaglandins. It is over-expressed in multiple cancers and has been associated 
      with diminished tumor immunity. Dendritic cells (DCs) are considered candidates 
      for cancer immunotherapy due to their ability to process and present antigens to 
      T cells and stimulate immune responses. However, DC-based vaccines have exhibited 
      minimal effectiveness against established tumors. In this study, we evaluated the 
      effect of short-term administration of the selective COX-2 inhibitor celecoxib on 
      the efficacy of DC-based vaccines in preventing and treating established 4T1 
      murine mammary tumors. We show that dietary celecoxib alone significantly 
      suppresses the growth of primary tumors and the incidence of lung metastases in 
      the prophylactic setting but is less effective against pre-established tumors. 
      However, we demonstrate that celecoxib administered after primary tumor 
      establishment synergizes with tumor lysate-pulsed DC and the adjuvant, GM-CSF, to 
      improve the antitumor immune response by suppressing primary tumor growth and 
      markedly reducing the occurrence of lung metastases. This triple combination 
      therapy elicits a tumor-specific immune response evidenced by elevated IFN-gamma 
      and IL-4 secretion by CD4+ T cells and results in increased infiltration of CD4+ 
      and CD8+ T cells to the tumor site. In addition, dietary celecoxib inhibits 
      angiogenesis evidenced by decreased vascular proliferation within the tumor and 
      serum vascular endothelial growth factor levels. These studies suggest that 
      short-term celecoxib therapy in combination with DC vaccines may be safely used 
      for treating metastatic breast cancer.
CI  - 2005 Wiley-Liss, Inc.
FAU - Hahn, Tobias
AU  - Hahn T
AD  - Department of Microbiology and Immunology, University of Arizona, Tucson, AZ 
      85724, USA.
FAU - Alvarez, Irene
AU  - Alvarez I
FAU - Kobie, James J
AU  - Kobie JJ
FAU - Ramanathapuram, Lalitha
AU  - Ramanathapuram L
FAU - Dial, Sharon
AU  - Dial S
FAU - Fulton, Amy
AU  - Fulton A
FAU - Besselsen, David
AU  - Besselsen D
FAU - Walker, Edwin
AU  - Walker E
FAU - Akporiaye, Emmanuel T
AU  - Akporiaye ET
LA  - eng
GR  - R01 CA94111-02/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cyclooxygenase Inhibitors)
RN  - 0 (Cytokines)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Administration, Oral
MH  - Animals
MH  - Breast Neoplasms/immunology
MH  - CD4-Positive T-Lymphocytes
MH  - CD8-Positive T-Lymphocytes
MH  - Cancer Vaccines/*immunology
MH  - Celecoxib
MH  - Cyclooxygenase 2/metabolism
MH  - Cyclooxygenase Inhibitors/administration & dosage/*pharmacology
MH  - Cytokines/analysis
MH  - Dendritic Cells/*immunology
MH  - Drug Administration Schedule
MH  - Female
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Immunotherapy
MH  - Mammary Neoplasms, Animal/*immunology/pathology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Neovascularization, Pathologic
MH  - Pyrazoles/administration & dosage/*pharmacology
MH  - Sulfonamides/administration & dosage/*pharmacology
EDAT- 2005/12/07 09:00
MHDA- 2006/04/29 09:00
CRDT- 2005/12/07 09:00
PHST- 2005/12/07 09:00 [pubmed]
PHST- 2006/04/29 09:00 [medline]
PHST- 2005/12/07 09:00 [entrez]
AID - 10.1002/ijc.21616 [doi]
PST - ppublish
SO  - Int J Cancer. 2006 May 1;118(9):2220-31. doi: 10.1002/ijc.21616.